FDA clears cell therapy XS-228 for ALS Phase 1 clinical trial
The U.S. Food and Drug Administration (FDA) has given Xellsmart Biopharmaceutical the go-ahead to start a Phase 1 clinical…
Articles by Michela Luciano, PhD
First patient dosed in a Phase 1 study testing AMX0114 in ALS
The first patient has been dosed in a Phase 1 clinical study testing AMX0114, an experimental therapy being developed by…
1st ALS patient enrolled in MN-166 expanded access program
The first patient has been enrolled in an expanded access program (EAP) trial evaluating MN-166 (ibudilast), Medicinova’s oral anti-inflammatory…
Denali halts extension of DNL343 arm in HEALEY ALS trial
Denali Therapeutics‘ oral candidate DNL343 has failed to reduce levels of an established biomarker of nerve cell damage in…
Pathmaker wins 3 new patents for neuromodulation technology in ALS
Pathmaker Neurosystems has received three new patents — two in the U.S. and one in Japan — that cover…
Tiziana seeking FDA OK to launch clinical trial of foralumab in ALS
Tiziana Life Sciences is seeking regulatory clearance in the U.S. to launch a Phase 2 clinical trial evaluating foralumab…
Woolsey secures additional funding to advance ALS therapy Bravyl
Woolsey Pharmaceuticals has extended its Series B preferred financing round, securing additional funds to continue advancing its ROCK inhibitor…